Bruno Carlos
Sangro Gómez-Acebo

2025

1. Clinical and dosimetric considerations for yttrium-90 glass microspheres radioembolization of intrahepatic cholangiocarcinoma, metastatic colorectal carcinoma, and metastatic neuroendocrine carcinoma: recommendations from an international multidisciplinary working group

   European Journal of Nuclear Medicine and Molecular Imaging

2. DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy

   Journal of Viral Hepatitis, Vol. 32, Núm. 2

3. Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study

   Hepatology

4. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study

   The Lancet, Vol. 405, Núm. 10474, pp. 216-232

5. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma

   Journal of Hepatology, Vol. 82, Núm. 2, pp. 315-374

6. Expression landscape of epigenetic genes in human hepatocellular carcinoma

   Journal of Physiology and Biochemistry

7. Health-related quality of life in patients with unresectable hepatocellular carcinoma treated with SIRT and nivolumab: a sub-analysis of the NASIR-HCC trial

   Journal of Patient-Reported Outcomes, Vol. 9, Núm. 1

8. Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA Phase 3 randomized clinical trial

   Hepatology

9. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis

   Journal of Hepatology, Vol. 82, Núm. 1, pp. 107-119

10. MORPHEUS-Liver provides a way forward in expanding the immunotherapy options for hepatocellular carcinoma

    Nature Reviews Clinical Oncology

11. Metabolomic liquid biopsy dynamics predict early-stage HCC and actionable candidates of human hepatocarcinogenesis

    JHEP Reports, Vol. 7, Núm. 5

12. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

    The Lancet, Vol. 405, Núm. 10492, pp. 1851-1864

13. Numerical assessment of the performance of a new multi side-hole catheter design in liver radioembolization

    Computers in Biology and Medicine, Vol. 187

14. Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

    Journal of Hepatology, Vol. 82, Núm. 2, pp. 258-267

15. Phosphatidylserine as a tumor target for CAR-T cell therapy

    Journal for ImmunoTherapy of Cancer, Vol. 13, Núm. 2

16. Prognostic value of circulating tumor DNA in different cancer types detected by ultra-low-pass whole-genome sequencing: a systematic review and patient-level survival data meta-analysis

    Carcinogenesis, Vol. 46, Núm. 1

17. Recommendations on Perihilar Cholangiocarcinoma. the Milan Jury-Based Consensus

    Annals of Surgery

18. Reply to: “Ruptured HCC: An entity in exile from the EASL Clinical Practice Guidelines!”: Ruptured HCC: Not exiled, but navigating an evidence vacuum

    Journal of Hepatology

19. Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma

    Journal of experimental & clinical cancer research : CR, Vol. 44, Núm. 1, pp. 13

20. Transarterial Radioembolisation with Y90 Resin Microspheres and the Effect of Reimbursement Criteria in France: Final Results of the CIRT-FR Prospective Observational Study

    CardioVascular and Interventional Radiology, Vol. 48, Núm. 2, pp. 205-220